Lonza Group stock holds steady as market value reaches CHF 39.47 billion
Published on 08/22/2026 at 08:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lonza Group AG (CH0013841017) held at 619.20 EUR on August 20, 2026, while market value stood at CHF 39.47 billion and the five-day move was 2.93%.
The latest Swiss-market snapshot also shows a year-to-date decline of 1.96%, which gives the rebound a narrower frame even after the recent bounce.
Trading stays tied to valuation
For investors, the main number is the gap between the short-term lift and the year-to-date performance. A 2.93% five-day gain against a 1.96% YTD decline leaves the shares without a clear trend break.
A separate market wrap for August 21, 2026 said Lonza was among the Swiss names that gained 1% to 1.55% as the SMI finished higher by 0.62% to 14,456.98 points.
What the latest reports say
Lonza's most recent reported half-year figures showed revenue of CHF 3.6 billion in the first half of 2026, with core EBITDA of CHF 875 million and a core EBITDA margin of 24.3%.
That was backed by underlying demand in the companys biologics and small-molecule network business, and the first-half margin stayed above the full-year 2025 level of 23.1%.
Business mix and product angle
Lonza's work spans biologics manufacturing, small-molecule drug substance, and integrated development services, with capsules and consumer-health exposure also part of the wider mix. Those businesses matter because the reported margin profile depends on how quickly higher-value projects ramp through the network.
Lonza has also been linking its growth case to capacity use and project execution, which makes the first-half margin level a better guide than the stock's one-day move alone.
Stock level to watch
Lonza Group shares traded at 619.20 EUR on August 20, 2026, with the market value at CHF 39.47 billion and the five-day change at 2.93%.
Fact box
Company: Lonza Group AG
ISIN: CH0013841017
Ticker: LONN
Exchange: SIX Swiss Exchange
Sector / Industry: Health Care / Life Sciences Tools & Services
Index membership: SMI
More on Lonza Group stock
The company's product base includes biologics, small-molecule manufacturing, and capsules.
